Physician profile
John Nelson
NPI 1699120964
$6,331.16
in general payments reported to CMS, 2019-2025
35 companies · $1,335 in 2025
The $1,335 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.67 · 2020: $419 · 2021: $1,109 · 2022: $987 · 2023: $1,243 · 2024: $1,211 · 2025: $1,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,789.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,046.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $752.54 | 2020-2025 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals Lp | $637.14 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $547.36 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $425.91 | 2020-2025 | |
| Amgen INC. | $357.49 | 2021-2025 | Otezla, Otezla, Repatha |
| Amarin Pharma, INC. | $306.48 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $272.38 | 2021-2024 | |
| Abbvie INC. | $246.95 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $199.52 | 2023-2025 | |
| Glaxosmithkline, LLC. | $195.53 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $145.06 | 2022-2025 | |
| Daiichi Sankyo INC. | $128.73 | 2021-2022 | |
| Esperion Therapeutics, INC. | $128.63 | 2020-2025 | Nexletol |
| Corcept Therapeutics | $104.93 | 2024-2025 | Korlym |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.